A study to evaluate acalabrutinib, in combination with the R-CHOP standard of care, for previously untreated mantle cell lymphoma in Spain

Trial Identifier: D8220L00087
Sponsor: AstraZeneca
Collaborator:
APICES SOLUCIONES, S.L.
Start Date: September 2025
Primary Completion Date: June 2027
Study Completion Date: December 2028

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
ES A Coruña, ES, 15006
ES Alcorcón, ES, 28922
ES Badalona, ES, 08916
ES Barcelona, ES, 08035
ES Barcelona, ES, 08036
ES Burgos, ES, 09006
ES Donostia, ES, 20014
ES Gijon, ES, 33206
ES Madrid, ES, 28007
ES Madrid, ES, 28005
ES Madrid, ES, 28029
ES Madrid, ES, 28006
ES Málaga, ES, 29010
ES Palma de Mallorca, ES, 07198
ES Salamanca, ES, 37007
ES Santa Cruz de Tenerife, ES, 38010
ES Santander, ES, 39008
ES Sevilla, ES, 41013
ES Valencia, ES, 46010
ES Valencia, ES, 46017
ES Vigo, ES, 36214